SAN FRANCISCO and SUZHOU, China, May 28, 2024 /PRNewswire/ Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that picankibart (R & D code: IBI112), a recombinant anti-interleukin 23p19 subunit (IL-23p19) antibody injection, has met all.
Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA | Taiwan News taiwannews.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taiwannews.com.tw Daily Mail and Mail on Sunday newspapers.
The ideal candidate "is averse to using systemic agents but whose disease is beyond the point where topical medicines alone will work," Craig A. Elmets, MD, said.
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Risankizumab Effective for Psoriasis Over 18 Months in Real World Settings hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.